ReviewCurrent pharmaceutical biotechnology2011
Anti-angiogenic peptides for cancer therapeutics.
Review in Current pharmaceutical biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it, 168 citations in OpenAlex.
- Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysisDiagnostic and interventional radiology (Ankara, Turkey) · 2024Pooled it
- The Dual Role of Natural Peptides in Cancer Therapy: Anticancer and Immunomodulatory Perspectives.Oncology research · 2026Review
- Lipid Remodeling and Metabolic Adaptation in Cancer Cell Membranes: A Platform for Membrane-Targeted Nanotherapy.Advances in experimental medicine and biology · 2026Review
- Comparative analysis of tissue-specific anticancer peptide prediction models: ACP-Boost framework.Frontiers in molecular biosciences · 2026Article
- Recent progress in the exploitation of anti-cancer small molecules targeting angiogenesis.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Cardiovascular Safety of VIAN-c4551, an Antiangiogenic Peptide Derived From Vasoinhibin.Drug development research · 2025Article
- BPFun: a deep learning framework for bioactive peptide function prediction using multi-label strategy by transformer-driven and sequence rich intrinsic information.BMC bioinformatics · 2025Article
- Type IV collagen derived non-collagenous domain α6 (IV) NC1 and its derivative fragments inhibit endothelial cell proliferation and attenuatesCytotechnology · 2025Article
- Novel Products as Promising Therapeutic Agents for Angiogenesis Inhibition.Current drug delivery · 2025Review
- Synergistic Efficacy of Dual-Target HSA-Based Delivery for HER and VEGFR Co-Blockade in Triple-Negative Breast Cancer.International journal of molecular and cellular medicine · 2025Article
- Extracellular matrix dysregulation in aging, calcification, and cancer diseases: insights into cellular senescence, inflammation, and novel therapeutic strategies.International journal of biological sciences · 2025Review
- Anti‑angiogenic effect ofInternational journal of oncology · 2025Article
- Improved prediction of anti-angiogenic peptides based on machine learning models and comprehensive features from peptide sequences.Scientific reports · 2024Article
- Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth.Cell death discovery · 2024Article
- Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth.Research square · 2023Article
- Characterisation of a novel crustin isoform from mud crab,In silico pharmacology · 2023Article
- Review
- Peptide therapeutics in the management of metastatic cancers.RSC advances · 2022Review
- The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview.Medicina (Kaunas, Lithuania) · 2022Review
- Biological aspects in controlling angiogenesis: current progress.Cellular and molecular life sciences : CMLS · 2022Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Peptides have emerged as important therapeutics that are being rigorously tested in angiogenesis-dependent diseases due to their low toxicity and high specificity. Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin, endostatin) several peptides have shown promise in pre-clinical and clinical studies for cancer. Peptides have been derived from thrombospondin, collagens, chemokines, coagulation cascade proteins, growth factors, and other classes of proteins and target different receptors. Here we survey recent developments for anti-angiogenic peptides with length not exceeding 50 amino acid residues that have shown activity in pre-clinical models of cancer or have been tested in clinical trials; some of the peptides have been modified and optimized, e.g., through L-to-D and non-natural amino acid substitutions. We highlight technological advances in peptide discovery and optimization including computational and bioinformatics tools and novel experimental techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.